Sorry, looks like we don't have enough of this product.
Does magnesium actually prevent migraines? The 4-Type Framework, 400-600mg elemental protocol, Peikert 1996 (41.6% attack reduction). UK 2026 Honest Guide.
Most UK supplement brands sell magnesium for migraines without telling you the things that actually matter: which type of migraine you have, how much elemental magnesium the trials used, why one famous trial worked and one failed, and why the official UK position is more conflicted than your search results suggest. This guide answers all of that — honestly.
Magnesium is the most clinically studied nutrient for migraine prevention. The American Academy of Neurology and American Headache Society rate it Level B evidence — "probably effective" — for migraine prophylaxis. The Migraine Trust, the UK's foremost patient charity, recommends 400–600mg daily for adults living with migraine. The British Association for the Study of Headache (BASH) acknowledges it as a viable option. NICE clinical guideline CG150, by contrast, does not routinely recommend it. That gap between the patient-facing UK authorities and the prescriber-facing UK guideline is not an accident — and it matters for how you should think about magnesium for your own migraines. This is the honest UK 2026 clinical guide.
If you read 10 UK supplement-brand articles on magnesium for migraines, you will see "magnesium helps reduce migraines" repeated 10 times. None of them will tell you that the clinical evidence is meaningfully different depending on which type of migraine you have. This is the first mistake of the UK content market on this topic.
Migraine is not a single condition. The International Classification of Headache Disorders (ICHD-3) recognises multiple subtypes, but for the purpose of choosing magnesium for prevention, four categories matter most: migraine with aura, migraine without aura, menstrually-related migraine, and chronic migraine. Each has different underlying neurology, and each has a different strength of evidence behind magnesium supplementation.
| Migraine type | Key features | Magnesium evidence strength | Suggested protocol |
|---|---|---|---|
| Type A — With aura | Visual disturbance, sensory changes, or speech changes preceding pain | Strongest. Mauskop & Varughese 2012; CSD-blocking mechanism | 400–600mg elemental daily; 12-week minimum trial |
| Type B — Without aura | Throbbing unilateral pain, photophobia, phonophobia, nausea — no aura | Moderate. Peikert 1996 (with and without aura mixed) | 400–600mg elemental daily; 12-week minimum |
| Type C — Menstrually-related | Attacks clustered around menstrual cycle (2 days before to 3 days after) | Strong. Facchinetti 1991; intracellular Mg deficit documented | 360–600mg elemental, can be cyclical (day 15 of cycle) |
| Type D — Chronic | 15+ headache days/month for 3+ months (≥8 migrainous) | Emerging. Limited dedicated trials; mechanism plausible | Magnesium as adjunct; pursue specialist plan |
If you don't yet know your type, the simplest test is whether you experience aura. Aura is the visual zig-zags, blind spots, flashing lights, tingling, or speech changes that precede the headache phase — usually by 15–60 minutes. Around one in three people with migraine experience aura. The clinical evidence for magnesium is strongest in this group because the underlying mechanism magnesium addresses — cortical spreading depression — is exactly what produces aura symptoms.
For Type C readers, the menstrual pattern can be subtle. Facchinetti et al. (1991) documented that intracellular magnesium levels drop in the days leading up to menstrual migraine attacks — a measurable biological correlate that explains why this population responds well to magnesium supplementation. If your attacks cluster around your cycle, this is your category, and the protocol can be timed accordingly. For more on the broader hormonal picture, see our Best Supplements for Perimenopause UK guide.
For Type D readers — chronic migraine — magnesium is rarely sufficient on its own. The dedicated trials are limited, and current UK practice in chronic migraine usually involves prescribed prophylactics (propranolol, candesartan, topiramate, CGRP-targeted agents) under specialist supervision. Magnesium is reasonable as an adjunct, but it is not the primary tool for this category.
The clinical evidence for magnesium is strongest in migraine with aura and menstrual migraine. Most UK content omits this distinction. The omission is not harmless — it determines whether you should expect magnesium to help.
Magnesium is not a painkiller. It does nothing to an active migraine attack the way ibuprofen, a triptan, or a CGRP-targeted medication would. What it does is something more upstream: it reduces the brain's susceptibility to the events that initiate migraine in the first place. Understanding the mechanism explains both why magnesium works as a preventive and why it doesn't work as an acute treatment.
Cortical spreading depression is a slow wave of intense neuronal and glial depolarisation that moves across the brain's surface at 2–6 mm per minute. As the wave passes, it produces brief electrical hyperactivity followed by prolonged neuronal silencing. CSD is widely accepted as the neurophysiological event responsible for migraine aura — the visual zig-zags, sensory changes, and speech disruption people with Type A migraine experience before headache onset.[1]
CSD is initiated by excessive glutamate release in the cortex, opening NMDA-type glutamate receptors and producing the cascade of ionic shifts that propagate the wave. Here is where magnesium becomes relevant: magnesium ions sit inside the NMDA receptor pore as a voltage-dependent blocker. When magnesium levels are adequate, the receptor's threshold for activation is higher and CSD is less easily triggered. When magnesium levels are low — as they have been measured to be in the brains, spinal fluid, and serum of people with migraine[2,3] — the receptor is more readily activated and the brain is more vulnerable to CSD events.
Magnesium is unusually multi-mechanistic for a single nutrient. In the context of migraine specifically, it acts through at least four pathways:
One of the least-discussed pieces of evidence in UK consumer content is Lodi et al. (2001), who used phosphorus magnetic resonance spectroscopy to measure cytosolic free magnesium and the free energy released by ATP hydrolysis in the brains of migraine and cluster headache patients.[4] They found that both metrics were significantly reduced in the occipital lobes of people with migraine — including those with hemiplegic migraine, where the magnesium deficit correlated with severity of neurological symptoms.
The interpretation: the brains of migraineurs may have a mitochondrial bioenergetic deficit, with reduced free magnesium contributing to inefficient ATP production. This is not a small finding. It moves magnesium from "general nutrient" status to "addressing a specific measurable deficit in the migraine brain." Almost no UK supplement brand cites this work. It is one of the most important pieces of the evidence base for taking magnesium seriously in this category.
Magnesium raises the threshold for cortical spreading depression (the event behind aura), reduces serotonin-driven cerebral vasoconstriction, and addresses a documented mitochondrial bioenergetic deficit in the migraine brain. This is upstream prevention — not acute relief.
If you search "magnesium for migraines UK" you will find UK supplement brands recommending it, US bodies endorsing it, The Migraine Trust supporting it — and NICE not routinely recommending it. The gap is real and worth understanding.
The Migraine Trust is the UK's principal patient charity for migraine. Its guidance, last updated in 2026, states that magnesium supplements may reduce frequency and severity of migraine attacks for some people, that the recommended dose is between 400mg and 600mg of elemental magnesium per day, and that magnesium is safe to take during pregnancy under medical advice.[5] This is one of the clearer institutional endorsements of any over-the-counter supplement for any condition in the UK.
The British Association for the Study of Headache (BASH), the UK's professional society for headache medicine, acknowledges magnesium as a potential preventive option in its 2019 guidelines.[6] The framing is closer to "available" than to "first-line", and BASH places greater emphasis on prescribed prophylactics (propranolol, topiramate, candesartan, amitriptyline) as the standard first-line options.
The National Institute for Health and Care Excellence (NICE) Clinical Guideline 150 on the diagnosis and management of headaches in over-12s, published in 2012 and updated subsequently, does not routinely recommend magnesium for migraine prophylaxis in primary care.[7] This is the most cited UK clinical guideline. It is also the most conservative — NICE guidelines are written for NHS primary care decision-making and require a higher evidence threshold than patient-charity guidance.
Across the Atlantic, the American Academy of Neurology and the American Headache Society published a joint evidence-based assessment of preventive migraine therapies in 2012, classifying magnesium as Level B evidence — "probably effective" — and recommending it should be considered for patients requiring migraine preventive therapy.[8] This rating remains in force.
NICE applies a conservative bar designed for NHS resource allocation. AAN/AHS, BASH, and The Migraine Trust apply a more pragmatic bar — magnesium is inexpensive, well-tolerated, safe in pregnancy, and has a coherent evidence base, so the cost-benefit profile is favourable even where the evidence quality is moderate rather than high. The honest position for a UK adult is: if you have migraine and you have not tried magnesium under a clinically reasonable protocol, the evidence is sufficient to consider it — most usefully in discussion with your GP, particularly if you are taking other medications or are pregnant. That is what The Migraine Trust recommends.
Where you should not be is reading aggressive marketing claims of "70% reduction" or "instant migraine relief" — those numbers do not exist in the clinical literature and they damage the credibility of an intervention that has a real, modest, useful effect when used properly.
Peikert, Wilimzig and Köhne-Volland randomised 81 migraine patients aged 18–65 to either 600mg/day of trimagnesium dicitrate or placebo for 12 weeks, following a 4-week baseline observation.[9] By weeks 9–12, attack frequency had reduced by 41.6% in the magnesium group versus 15.8% in placebo (p < 0.05). Migraine days per month and rescue medication consumption both decreased significantly in the magnesium group.
The detail most UK content omits is the timing. The effect did not emerge in week 2 or week 4. It emerged in weeks 9–12. If you take a magnesium supplement for two weeks and conclude it does not work, you have not actually tested it. The minimum clinically meaningful trial period for migraine is 12 weeks — and ideally 16 to confirm whether the trajectory is stable. This is one of the most important practical takeaways from the evidence base and one of the most consistently lost in marketing-driven content.
In the same year, Pfaffenrath et al. ran a comparable trial — but used 243mg/day of magnesium-L-aspartate-hydrochloride-trihydrate.[10] They found no significant benefit. Almost half of the magnesium group experienced diarrhoea, suggesting poor absorption and intestinal flushing. The form was poorly bioavailable and the dose was lower than Peikert's.
The conventional reading of Pfaffenrath 1996 is "the trial that failed" or "evidence against magnesium". The accurate reading is the opposite: the trial demonstrated that magnesium form and bioavailability matter. If your salt is poorly absorbed and your dose is too low, you will not see the Peikert effect — not because magnesium doesn't work, but because you haven't delivered enough of it to the relevant tissue. This is the empirical foundation of the entire elemental-magnesium-and-bioavailability conversation we cover in our cluster — particularly in Elemental Magnesium: The 14% Rule and Magnesium Glycinate vs Citrate.
Facchinetti et al. randomised 20 women with menstrual migraine to either 360mg/day of magnesium pyrrolidone carboxylic acid or placebo, taken from day 15 of the cycle until the next menses, over two cycles.[11] The magnesium group showed significant reduction in Pain Total Index (PTI) and Menstrual Distress Questionnaire (MDQ) scores. Critically, intracellular magnesium concentrations in lymphocytes and polymorphonuclear cells increased with treatment, and an inverse correlation between PTI and intracellular Mg was demonstrated.
The implications for Type C readers are substantial. First, a cyclical magnesium protocol — started two weeks before menses, continued through — has direct trial evidence behind it. Second, the mechanism is documented: intracellular magnesium is depleted in the days leading up to menstrual migraine attacks, and supplementation restores it. Third, the dose is lower than Peikert's 600mg — 360mg/day was sufficient in this population.
Köseoglu et al. ran a double-blind placebo-controlled trial of 600mg/day magnesium citrate in patients with migraine without aura, using visual evoked potentials and SPECT imaging as outcome measures alongside clinical assessment.[12] The trial supported a beneficial effect in this subtype, extending the Peikert findings to a population that excludes the aura-mediated mechanism — important because it suggests magnesium works through more than just the CSD pathway.
In a 2012 paper in the Journal of Neural Transmission, Mauskop and Varughese argued that all migraine patients should be considered for magnesium treatment.[13] Their reasoning: the safety profile is excellent, the cost is low, the mechanism is plausible and partially proven, deficiency is more common than commonly assumed in migraine populations, and even a modest response represents meaningful symptom reduction at minimal risk. The paper is one of the most quoted in modern migraine-and-magnesium literature, and the title alone is a useful frame for thinking about whether to try it.
Cochrane systematic reviews have rated the quality of evidence on magnesium for migraine as moderate to low overall — primarily because trials are small, formulations vary, durations are short, and methodological consistency is limited.[14] Teigen and Boes (2015) in Cephalalgia reviewed the literature and noted that the evidence supports magnesium as a reasonable preventive option, with the strongest signal in patients with aura, menstrual migraine, and documented low magnesium status.[15]
Every clinical guideline and trial uses elemental magnesium as the dose unit. The Migraine Trust says 400–600mg elemental. The AAN/AHS classification refers to elemental dose. Peikert 1996 used 600mg of trimagnesium dicitrate, which delivered approximately 96mg of elemental magnesium — and yet this is the trial cited as the foundational positive result. The numbers do not add up cleanly because magnesium supplementation is genuinely confusing on this point. This section makes it concrete.
Different forms of magnesium contain different percentages of elemental magnesium by weight. The label on a UK supplement bottle frequently shows the total salt weight, not the elemental content. To match the clinical target dose, you need to know both numbers.
| Magnesium form | Elemental % | Bioavailability | Dose to deliver 400mg elemental | Migraine use suitability |
|---|---|---|---|---|
| Magnesium oxide | ~60% | Low (~4% absorbed) | ~670mg total (but absorption-limited) | Inexpensive, GI side effects common |
| Magnesium citrate | ~16% | Moderate-to-high | ~2,500mg total | Most clinical-trial use (Peikert) |
| Magnesium glycinate (bisglycinate) | ~14% | High; gentle on GI | ~2,850mg total | Best for daily tolerability |
| Magnesium taurate | ~9% | High | ~4,440mg total | Less studied for migraine specifically |
| Magnesium L-threonate | ~7% | Brain-penetrant | ~5,700mg total | Cognitive use; emerging migraine data |
| Magnesium malate | ~6.5% | Moderate-high | ~6,150mg total | Fatigue/fibromyalgia context |
The practical implication is that the form you choose constrains the dose you need. If you want 400mg elemental from magnesium glycinate, you need around 2,850mg of magnesium glycinate by total salt weight per day — frequently three to four capsules. The same elemental load from citrate is around 2,500mg total weight. From oxide, only around 670mg total weight, but because oxide is poorly absorbed, the absorbed dose may still be lower than expected.
For more on this calculation across different scenarios, our Elemental Magnesium article and our Best Magnesium Glycinate UK deep dive go further. The short version: for migraine specifically, magnesium glycinate is excellent for tolerability but requires a higher daily count of capsules to reach trial-comparable elemental dose. Many people use a glycinate-citrate combination — citrate for headline elemental efficiency, glycinate for gentle daily tolerability and the bonus calming effect of glycine. The Stress & Focus Stack and Complete Wellness System include magnesium glycinate as a foundational input for this exact reason.
Peikert 1996 used trimagnesium dicitrate. Many UK pharmacy and supplement-brand recommendations default to citrate as a result. It is well-absorbed, has a documented effect at 600mg/day, and is the form with the most direct trial evidence for migraine. The trade-off is its mild laxative effect — which is helpful for some users and inconvenient for others.
Glycinate binds magnesium to the amino acid glycine, producing a chelate that is gentle on the gastrointestinal tract and well-absorbed. It is the form most often recommended for daily long-term use, particularly for people who experience GI side effects with citrate or oxide. The trade-off is the lower elemental percentage by weight — more capsules per day to hit 400–600mg elemental — and the absence of large dedicated migraine trials using this specific form. Mechanistically there is no reason to expect a different outcome; the magnesium is the same magnesium once absorbed. See our Magnesium Glycinate vs Citrate guide for the full comparison.
Magnesium oxide is the cheapest form and the form most often used in older clinical trials, including some of the foundational migraine work. The American Migraine Foundation recommends it at 400–500mg daily. The trade-off is poor bioavailability — only around 4% is absorbed — and a high rate of GI side effects. It is reasonable as a starting point if cost is a primary consideration and the user tolerates it, but most modern UK practice has shifted toward citrate or glycinate.
Threonate was developed at MIT for its ability to penetrate the blood-brain barrier and raise CNS magnesium levels. The migraine evidence base for threonate specifically is small and emerging rather than established. It is reasonable for users who want a cognition-focused magnesium form and are prepared for the higher per-capsule price.
For most UK adults considering magnesium for migraine prevention, the practical sequence is:
| Migraine type | Elemental dose target | Trial-comparable form | Expected timeline to effect |
|---|---|---|---|
| Type A — With aura | 400–600mg elemental daily | Citrate or glycinate; Peikert protocol | Effect emerges weeks 9–12 |
| Type B — Without aura | 400–600mg elemental daily | Citrate (Köseoglu 2008 protocol) | Effect emerges weeks 9–12 |
| Type C — Menstrual | 360–600mg elemental, day 15 to menses (Facchinetti protocol) | Citrate, glycinate, or pyrrolidone | Effect across 2 cycles |
| Type D — Chronic | Adjunct to specialist plan; 400mg elemental typical | Per specialist guidance | Modest effect; primary tools are prescription |
The most common error is stopping too early. If you are trialling magnesium for migraine prevention, the minimum honest assessment window is 12 weeks. Below that, you have not tested it — you have sampled it. The Peikert 1996 effect emerged in weeks 9–12 specifically. The Facchinetti 1991 effect was clear by the second menstrual cycle. Anything sooner is noise or placebo.
Most UK magnesium supplements were not designed with migraine prevention specifically in mind. They were designed for sleep, anxiety, or general supplementation, and the labelling reflects that. If you are choosing magnesium for migraine, these are the five markers to verify before buying.
Marker 1 — Elemental magnesium stated clearly on the label. Not just "magnesium glycinate 1,000mg" — but "magnesium glycinate 1,000mg providing 140mg elemental magnesium". UK NRV regulations expect this disclosure. Brands that hide it are usually hiding a small elemental load behind a big-looking total mg number.
Marker 2 — Form named (glycinate, citrate, oxide, taurate, threonate). "Magnesium" with no form named is the lowest-quality position. Migraine-grade products specify the form, and ideally state the rationale (glycinate for tolerability, citrate for elemental efficiency).
Marker 3 — Adequate per-day dose architecture. A bottle of 30 capsules at 100mg elemental per capsule means 1 capsule per day delivers 100mg, well below the 400–600mg target. Verify the daily serving (often 3–4 capsules for glycinate) is realistic and matches the trial-comparable elemental dose.
Marker 4 — UK-made, GMP-certified, third-party tested. UK GMP manufacturing is the baseline. Third-party testing for heavy metals (lead, mercury, cadmium, arsenic) is the meaningful additional signal. UK-made products with COA disclosure rank highest.
Marker 5 — No magnesium stearate as a primary excipient, no proprietary blends hiding the dose. "Proprietary blend" labelling allows brands to omit specific magnesium content. Migraine-grade products show the exact dose of each form per capsule.
Our Magnesium Glycinate is formulated to all five markers — UK-made, elemental content stated, no proprietary blend, third-party tested, glycinate form for tolerability. For the full UK market comparison, see Best Magnesium Glycinate UK 2026 and our wider Magnesium Supplements Guide.
Migraine is unusual among supplementable conditions in that it has a measurable, countable endpoint — attacks per month — and clear secondary metrics that the clinical literature tracks. The tracker below mirrors what migraine trials measure, scaled down to a 60-second weekly entry you can keep on your phone or in a notebook.
| Marker | What you record | What good progress looks like |
|---|---|---|
| 1. Attack frequency | Number of distinct migraine attacks this week | Progressive reduction across weeks 9–12 (per Peikert) |
| 2. Attack intensity | Peak pain rating per attack, 1–10 VAS | Modest reduction; magnesium primarily affects frequency more than intensity |
| 3. Attack duration | Hours from onset to resolution per attack | Modest reduction signal in some trials |
| 4. Aura presence | Yes/no per attack; type if present (visual, sensory, speech) | Reduced frequency in Type A users; documents your category |
| 5. Menstrual correlation | Day of cycle if applicable; cycle phase | Confirms Type C pattern; informs cyclical dosing |
How to use the tracker: Record at the end of each week — Sunday evening works well. Establish baseline for 4 weeks before starting magnesium. Continue tracking weekly for at least 12 weeks of supplementation. Compare the 4-week baseline average against the weeks 9–12 average. This mirrors the Peikert 1996 trial methodology and is the most honest way to assess whether magnesium is working for your migraines.
If you prefer a digital tool, The Migraine Trust offers a free migraine diary, and the Migraine Buddy app records the same markers automatically. Whatever tool you use, the principle is the same — track structured data, not impressions, and give it 12 weeks.
An honest UK 2026 guide on magnesium for migraine has to acknowledge that magnesium is not the only nutrient with credible evidence. The Migraine Trust explicitly lists three supplements as having evidence in migraine prevention: magnesium, riboflavin (vitamin B2), and coenzyme Q10.[5] Many UK adults with migraine respond best to a combination rather than to any single one.
Riboflavin at 400mg/day for at least three months has been included in UK clinical guidelines for headache management as a potential treatment for migraine prevention. The mechanism centres on improved mitochondrial energy production — the same bioenergetic theme as magnesium, but addressed through a different cofactor. The evidence base is moderate, and tolerability is excellent.
CoQ10 is a mitochondrial antioxidant. Clinical trials have shown that it may reduce frequency, severity and duration of migraine attacks. The Migraine Trust notes that doses of at least 100mg per day are usually suggested, often higher. CoQ10 is not recommended during pregnancy due to insufficient safety data.
Magnesium + B2 + CoQ10 is the most evidence-based three-nutrient combination for migraine prevention in the modern UK literature. Some commercial products combine all three. Whether you use a combination product or three separate supplements is a question of preference and dose precision — combination products often underdose one component to fit the formulation. The dose targets to verify are 400–600mg elemental magnesium, 400mg riboflavin, and at least 100mg CoQ10.
None of this is medical advice — discuss any preventive strategy with your GP, particularly if you take other medications. The point is that "magnesium for migraine" is rarely the complete answer; for many users it is one well-evidenced piece of a broader nutrient strategy.
Magnesium non-response is well-documented in the trial literature. Before concluding it does not work for your migraines, walk through these.
If your magnesium glycinate provided 100mg elemental per capsule and you took one capsule per day, your trial dose was 100mg elemental — well below the 400–600mg target. Re-read the Elemental Calculator in Section 5 and verify your actual elemental intake before concluding non-response.
The Pfaffenrath 1996 trial showed that the wrong form at the wrong dose produces no benefit. If your supplement was magnesium-L-aspartate or an unspecified salt, the form may have been the bottleneck. Consider switching to citrate, glycinate, or a citrate-glycinate combination.
Peikert 1996 showed the effect at weeks 9–12 specifically. If you stopped at week 4 because "it wasn't working", you stopped before the effect would emerge. The minimum honest trial period is 12 weeks at trial-comparable elemental dose.
Type D (chronic migraine) typically requires specialist treatment, not nutritional supplementation alone. If you have 15+ headache days per month, the right path is GP referral to a headache specialist or neurologist — not increased magnesium dosing.
If your migraines are driven primarily by sleep deprivation, alcohol, dehydration, hormonal contraception with aura (which is contraindicated and warrants GP review), or medication-overuse headache, magnesium will not solve the upstream problem. Migraine management requires multi-factor work, and our broader cluster — including Best Supplements for Sleep UK and Best Supplements for Stress UK — covers the adjacent levers.
If you have given magnesium a full 12-week trial at correct dose without response, the next reasonable step is adding riboflavin 400mg and CoQ10 at 100mg+ for a further 12 weeks. The Migraine Trust trio is more clinically grounded than any single-nutrient escalation.
Migraine that has not responded to a structured 12-week magnesium trial, especially if combined with B2 and CoQ10, is a reasonable point to escalate. UK NICE guidelines and BASH recommend prescribed prophylactics — propranolol, candesartan, topiramate, amitriptyline, or CGRP-targeted agents — for people with significant migraine burden. Supplements are an adjunct to, not a replacement for, appropriate medical care.
Magnesium is cleared by the kidneys. People with chronic kidney disease (CKD) or significantly reduced renal function should discuss magnesium supplementation with their nephrologist before starting, as elimination is impaired and accumulation can occur. This is one of the few populations where magnesium supplementation requires clinical oversight.
Magnesium can interfere with the absorption of several common medications when taken at the same time. Space magnesium at least 4 hours apart from:
The UK Nutrient Reference Value (NRV) for magnesium is 375mg/day from total intake (food + supplements). The EFSA Tolerable Upper Intake Level for supplemental magnesium specifically is 250mg/day in adults — note this is from supplements, separate from dietary magnesium.[16] The 400–600mg elemental dose used in migraine trials and recommended by The Migraine Trust exceeds this supplemental upper level, which is why these higher doses should be discussed with a GP or pharmacist.
The Migraine Trust notes that magnesium is considered safe during pregnancy at appropriate doses. The American Migraine Foundation rates magnesium oxide up to 400mg as pregnancy category A. Discuss specific dosing during pregnancy with your GP or midwife.
Magnesium is sold in the UK as a food supplement under the Food Standards Agency and MHRA framework. Supplements cannot legally be marketed to "treat, cure, or prevent" migraine — only to contribute to normal nervous system or muscle function within EFSA approved-claim wording. Brands making disease-prevention claims about magnesium are operating outside the UK regulatory framework. Adverse effects from any supplement can be reported through the MHRA Yellow Card scheme.
New-onset migraine over age 50, sudden change in migraine pattern, migraine with progressive neurological symptoms, or migraine with aura combined with combined hormonal contraception all warrant prompt GP review rather than supplement-led management. Supplements support, they do not replace, clinical assessment.
One question UK adults considering magnesium frequently ask is: how does it compare to the medications my GP would prescribe? This section is the honest answer.
Propranolol is the most commonly prescribed migraine prophylactic in UK primary care, recommended in NICE CG150 and BASH guidelines. Effect sizes in clinical trials are larger than magnesium's — roughly 50% reduction in attack frequency in responders, with the trial-comparable dose at 80–240mg modified-release per day. The trade-offs are real: fatigue, exercise intolerance (relevant for active adults), contraindicated in asthma, and potential mood effects. Magnesium's effect size is smaller, but its tolerability profile is excellent for most users.
Candesartan 4–16mg has emerged as a strong first-line option in UK practice for adults who do not tolerate or have contraindications to propranolol. Trial evidence shows comparable effect sizes. Tolerability is generally good; the main caveats are blood pressure effects and contraindication in pregnancy. Magnesium does not compete with candesartan — it operates through different mechanisms and can sit alongside it.
Topiramate is a more potent prophylactic with a meaningfully heavier side-effect burden (cognitive blunting, weight changes, paraesthesia). It is used when first-line options are insufficient. Patients on topiramate frequently report that adding magnesium provides additional benefit at low marginal risk.
Low-dose amitriptyline (10–75mg at night) is used for migraine prevention particularly when sleep disturbance and tension-type headache also feature. Anticholinergic side effects are the main caveat. Magnesium is non-conflicting and frequently used alongside.
Erenumab, fremanezumab, galcanezumab and atogepant/rimegepant represent the modern frontier of migraine prevention, with significantly larger effect sizes than older agents. NICE has approved these for chronic and high-frequency episodic migraine after specific prior-treatment criteria. They are not a magnesium replacement — they are specialist-prescribed treatments for higher-burden migraine. Magnesium remains a reasonable adjunct in users on CGRP-targeted therapy.
Magnesium is not a substitute for evidence-based prescribed prophylaxis when migraine burden is high. It is, however, a reasonable first-step option for users with episodic migraine who want to try a low-risk, well-tolerated intervention before escalating to prescription medication — and a reasonable adjunct alongside prescribed therapy for additive benefit at minimal risk. The two are not in competition; they sit on the same intervention spectrum at different points.
This is a conversation to have with your GP. Migraine is a serious neurological condition, and the right intervention depends on attack frequency, severity, response to acute treatment, comorbidities, and quality of life impact. Supplements support — they do not replace — appropriate clinical care.
Most users who try magnesium for migraine and see partial benefit can extract significantly more from a more integrated approach. Migraine is multi-factorial — sleep, hormones, stress, hydration, diet, light exposure, posture, and genetics all interact. The strategy below is what an evidence-led migraine adult would put in place, with magnesium as one piece rather than the entire answer.
Magnesium 400–600mg elemental, riboflavin (B2) 400mg, and CoQ10 100mg+ — the Migraine Trust trio — represent the most evidence-based three-nutrient stack for migraine prevention. Adding omega-3 (1–2g EPA+DHA) supports the broader anti-inflammatory case. The combination matters more than any single nutrient.
Sleep deprivation and irregular sleep timing are among the most consistent migraine triggers in the trial literature. Regular wake times (variability under 30 minutes) and 7–8 hours of sleep daily are foundational. If sleep is a known migraine trigger, magnesium glycinate in particular has a dual role — migraine prevention and sleep support through the glycine component. See our Best Supplements for Sleep UK and Best Magnesium for Sleep UK for the sleep architecture detail.
Chronic HPA-axis activation is a recognised migraine trigger, particularly for the "weekend migraine" pattern seen in cortisol-withdrawal headache. Magnesium contributes here too — it modulates the HPA axis directly and supports parasympathetic tone — but for HPA-driven migraine pattern, pairing magnesium with an adaptogen like ashwagandha addresses the upstream load. Our Magnesium and Cortisol and Best Supplements for Anxiety UK guides cover this layer in detail. The Stress & Focus Stack combines KSM-66® ashwagandha with lion's mane for users wanting the integrated adaptogenic approach.
The Lodi 2001 finding of reduced occipital cortex magnesium and impaired ATP hydrolysis points to a broader brain bioenergetic story in migraine. Cognitive overload, screen exposure, and prolonged mental fatigue are all reasonable triggers in this frame. Supporting cognitive resilience alongside magnesium — through structured rest, light hygiene, and where appropriate, neurotrophic support — is part of the integrated picture. Our Lion's Mane for Memory UK article covers the cognitive-load angle in depth.
Menstrual migraine is hormonally driven, and a magnesium-only approach captures part but not all of the picture. Cyclical magnesium dosing (Facchinetti protocol — day 15 through menses) is the foundation. For users approaching perimenopause, hormonal fluctuation itself becomes a primary trigger and the conversation broadens. Our Best Supplements for Perimenopause UK guide covers the hormonal architecture relevant to Type C migraineurs across the menopausal transition.
For users who want the integrated approach in a single regimen, the Complete Wellness System brings together magnesium glycinate, ashwagandha, lion's mane, probiotics, and collagen — covering the foundational, adaptogenic, neurotrophic, and structural layers in one stack. For users focused on the stress-cognitive axis specifically, the Stress & Focus Stack pairs ashwagandha with lion's mane. Magnesium glycinate sits as the foundational input in both. For more on combining magnesium with adaptogens specifically, see Magnesium and Ashwagandha Together.
Common migraine triggers — alcohol (red wine particularly), aged cheeses, processed meats, citrus, MSG, aspartame, sleep disruption, dehydration, hormonal contraceptives in those with aura, and weather changes — vary significantly between individuals. A migraine diary alongside the 5-Marker Tracker often identifies one or two triggers worth modifying. The Migraine Trust provides a structured diary template.
Hydration (2L+ water daily), regular meals (avoiding skipped meals and prolonged fasts unless deliberately managed), aerobic exercise (30 minutes, 3-5 times weekly), and caffeine moderation (under 200mg daily, consistent timing) form the lifestyle baseline. None of these are revolutionary, all of them have evidence behind them, and the cumulative effect across 12 weeks frequently outweighs the impact of any single supplement.
The honest framing: magnesium is a high-leverage, low-risk piece of a broader strategy. Treated as a standalone fix, it underperforms expectations. Treated as one well-evidenced piece of an integrated approach, it earns its place in the regimen.
Clinical evidence supports magnesium for migraine prevention, particularly in migraine with aura and menstrual migraine. The American Academy of Neurology and American Headache Society rate it Level B evidence — "probably effective". The Migraine Trust recommends 400–600mg elemental daily. The evidence is strongest for prevention, not acute treatment, and effects typically emerge over 9–12 weeks rather than immediately.
The Peikert 1996 foundational trial showed effect emerging in weeks 9–12, not earlier. The Facchinetti 1991 menstrual migraine trial showed effect across two menstrual cycles. The honest expectation is a 12-week minimum trial before assessing whether magnesium is helping. Anyone telling you to expect results in days or weeks is selling enthusiasm rather than evidence.
Magnesium citrate has the most direct trial evidence (Peikert 1996, Köseoglu 2008) and is the form most commonly used in clinical practice. Magnesium glycinate has excellent tolerability and is the most practical form for long-term daily use, though it has fewer dedicated migraine trials. Many users combine citrate and glycinate to balance elemental efficiency with GI comfort. See our Magnesium Glycinate vs Citrate comparison.
The Migraine Trust and the AAN/AHS recommend 400–600mg elemental magnesium per day. Critically, this is elemental magnesium, not total salt weight. To deliver 400mg elemental from magnesium glycinate requires around 2,850mg of total salt; from citrate, around 2,500mg. Verify the elemental content on your label, not just the total mg. Discuss higher doses with your GP, particularly because supplemental magnesium above 250mg/day exceeds the EFSA tolerable upper level.
Oral magnesium is a preventive intervention, not an acute treatment. It will not abort an active migraine. Intravenous magnesium sulfate (1–2g) has been used in clinical settings for acute migraine treatment, particularly in those with aura, but this is a hospital-administered intervention, not a self-treatment route. For acute relief, NICE guidance supports NSAIDs and triptans under appropriate prescription.
The Migraine Trust notes that magnesium is generally considered safe during pregnancy at appropriate doses. The American Migraine Foundation classifies magnesium oxide up to 400mg as pregnancy category A. Always discuss specific dosing during pregnancy with your GP or midwife, particularly because migraine pattern can change in pregnancy.
NICE applies a conservative evidence bar designed for NHS resource allocation in primary care. The Migraine Trust, BASH, and AAN/AHS apply a more pragmatic bar that weighs the favourable cost, safety, and benefit profile of magnesium. The gap is genuine and explains why patient-charity guidance is more supportive than the prescribing guideline. None of this means NICE is wrong — it means NICE is conservative, and conservative is appropriate for population-level guideline design.
Magnesium has no documented pharmacological conflicts with triptans, propranolol, candesartan, topiramate, amitriptyline, or CGRP-targeted agents. Space magnesium at least 4 hours apart from tetracycline/quinolone antibiotics, bisphosphonates, and levothyroxine to avoid absorption interference. Always notify your prescriber about any supplement use.
The mineral is the same; the use-case and protocols differ. For migraine, the trial-comparable elemental dose is higher (400–600mg) and the form most studied is citrate. For anxiety and sleep, glycinate is the more common form for its gentle calming effect and lower GI burden, and effective doses are often lower. See our Magnesium Glycinate for Anxiety and Best Magnesium for Sleep UK guides for those specific contexts.
Yes — the evidence for Type C (menstrual migraine) is among the strongest for magnesium. Facchinetti 1991 used 360mg/day from day 15 of the cycle through menses, with significant reductions in pain index and premenstrual symptoms, supported by measurable increases in intracellular magnesium. A cyclical protocol matches the underlying biology better than continuous dosing for this subtype.
The Migraine Trust notes that supplements can be considered for children with migraine, but doses differ and discussion with the GP or paediatrician is essential before starting. Paediatric migraine protocols are outside the scope of an adult-focused guide — please involve a clinician.
The most common side effect is diarrhoea, particularly with citrate or oxide at higher doses. Glycinate is the form with the lowest GI side-effect rate. Other potential effects include nausea, low blood pressure (rare), and at very high doses, magnesium toxicity in people with impaired kidney function. Dose reduction or form switching usually resolves GI symptoms. Our Is 400mg of Magnesium Glycinate Too Much? covers tolerability in detail.
The Migraine Trust supports all three as preventive supplements with evidence. The combination — magnesium 400–600mg, riboflavin 400mg, CoQ10 at least 100mg — is the most evidence-based three-nutrient stack for migraine prevention. Whether you use a combination product or three separate supplements depends on dose precision and preference. Combination products often underdose one component to fit the formulation, so verify the doses match the targets.
Cortical spreading depression (CSD) is a slow wave of intense neuronal activity moving across the brain's surface, widely accepted as the event behind migraine aura. CSD is glutamate-driven and activates NMDA receptors. Magnesium ions block the NMDA receptor pore at rest, raising the threshold for CSD initiation. This mechanism is the primary explanation for magnesium's stronger evidence in migraine-with-aura specifically.
Identify your migraine type using the framework in Section 1. Choose a quality magnesium supplement using the 5-Marker Checklist in Section 8. Start with magnesium glycinate at 300mg elemental, building toward 400–600mg over 1–2 weeks. Begin the weekly tracker on day one. Reassess at week 12. Our flagship product is Magnesium Glycinate, formulated to the five quality markers and UK MHRA/FSA compliant.
Magnesium has the strongest evidence base of any nutrient for migraine prevention. The American Academy of Neurology and American Headache Society rate it Level B "probably effective". The Migraine Trust, the UK's foremost patient charity, recommends it. The mechanism is biologically coherent — NMDA receptor blockade raises the threshold for cortical spreading depression, the event behind aura. Brain magnesium levels are demonstrably lower in migraineurs (Lodi 2001). And the Peikert 1996 foundational trial showed a 41.6% reduction in attack frequency at 600mg elemental for 12 weeks.
It is also not a guaranteed migraine cure, the official UK position is conflicted (NICE conservative, Migraine Trust supportive), and the gap between a clinically meaningful magnesium protocol and a poorly-formulated marketplace supplement is substantial. The Elemental Calculator in Section 5 and the 5-Marker Quality Checklist in Section 8 are the two practical tools that turn the evidence into something you can actually act on.
If your migraine is Type A (with aura) or Type C (menstrual), magnesium has the strongest evidence base for your category and a 12-week trial at 400–600mg elemental daily is a reasonable starting protocol. If your migraine is Type B (without aura), the evidence is moderate but still supportive — same protocol. If your migraine is Type D (chronic), magnesium is reasonable as an adjunct, but the primary pathway is specialist medical care. Whatever your category, the minimum honest trial period is 12 weeks, the tracker matters because perception is noisy, and the supplement does not replace appropriate medical assessment for new, worsening, or atypical migraine.
For our own UK-made magnesium glycinate, formulated against the five quality markers, see Magnesium Glycinate. For the broader picture across the cluster, see Best Magnesium Glycinate UK 2026, Magnesium Supplements Guide, and our editorial hub at Science-Backed.
Migraine is one of the most disabling conditions worldwide, and one of the most under-treated. The evidence for magnesium is not perfect, but it is good — and it is meaningful. If you've read this far, you have more clinical context than most people who walk into a UK pharmacy looking for migraine support. Use it well, give it 12 weeks, and discuss with your GP.
Lion's Mane and Ashwagandha. Together, by design.
SHOP THE STRESS & FOCUS STACK
